Top Companies in the Topical Drug Delivery

The global topical drug delivery market is expected to reach USD 409.0 billion by 2030 from USD 268.4 billion in 2025, at a CAGR of 8.8% during the forecast period. The growth of the topical drug delivery market is mainly driven by factors such as the growing prevalence of skin diseases; the high demand for drugs that can be self-administered; the increasing prevalence of chronic diseases, which is due to the rise in the geriatric population; rising investments in pharmaceutical R&D; and switching from conventional needle injections to transdermal patches.

• In January 2025, Bayer Consumer Health entered the menopause category for the first time in the UK by introducing the new brand, CanesMeno–an expertly crafted digital education resource and scientifically-backed product range. CanesMeno Hydration & Comfort Gel in this range, contains Ectoin to provide fast relief for up to five days, from vaginal atrophy symptoms associated with menopause such as dryness, itching and burning.
• In January 2024, Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics, released the US launch of CABTREO (clindamycin, adapalene, benzoyl peroxide) Topical Gel, 1.2%/0.15%/3.1% indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
• In June 2022, Novartis announced that it had acquired Kedalion Therapeutics and its AcuStream technology. This innovative device may have the potential to facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye. The acquisition enhances the company’s ophthalmic portfolio, advancing efforts to investigate transformative ophthalmic methods to address unmet patient needs in front-of-eye conditions.

The global topical drug delivery market is fragmented, with various players governing less than 25% of the market share. Some of the major players in the market are Johnson & Johnson Private Limited (US), Galderma (Switzerland), Bayer AG (Germany), Novartis AG (Switzerland), AbbVie Inc. (US), Glenmark Pharmaceuticals Ltd. (India), GSK Plc. (UK), Bausch Health Companies Inc. (Canada), Hisamitsu Pharmaceuticals Inc. (Japan), Cipla (India), and Viatris Inc. (Mylan N.V.) (US).

To know about the assumptions considered for the study download the pdf brochure

Johnson & Johnson Private Limited (US): The company primarily focuses on human health and well-being. J&J operates through two business segments: Innovative Medicine and MedTech. Topical drug delivery products fall under the Innovative Medicine segment, which is focused on six therapeutic areas: Immunology (e.g., rheumatoid arthritis, inflammatory bowel disease, and psoriasis), Infectious Diseases (e.g., HIV/AIDS), Neuroscience (e.g., mood disorders, neurodegenerative disorders, and schizophrenia), Oncology (e.g., prostate cancer and hematologic malignancies), Cardiovascular and Metabolism (e.g., thrombosis and diabetes), and Pulmonary Hypertension (e.g., Pulmonary Arterial Hypertension). The company has a strong presence across North America, Europe, the Asia Pacific, and Africa.

Galderma (Switzerland) offers premium brands and services across injectable aesthetics, dermatological skincare, and therapeutic dermatology. The company provides topical products under all three segments. Injectable Aesthetics consists of hyaluronic acid (HA) fillers and botulinum neuromodulators. Dermatological skincare consists of consumer care brands such as Cetaphil, with its wide range of skincare products for all ages; Benzac and Differin OTC for mild-to-moderate acne; and Loceryl, used to treat fungal nail infections. The company operates globally with research and development centers and manufacturing sites throughout the Asia Pacific, Europe, the Middle East, Africa, and North & Latin America.

Market Ranking:

The top five companies for the topical drug delivery market are Johnson & Johnson Services, Inc. (US), Galderma (Switzerland), Bayer AG (Germany), Novartis AG (Switzerland), AbbVie Inc. (US). Johnson & Johnson Services, Inc. (US) stands out for its diverse product portfolio that includes transdermal patches, nasal sprays, creams, ointments solutions along with its strategic partnerships. Galderma (Switzerland) uses R&D and product innovations to maintain a strong presence in the market. Bayer AG’s (Germany) position is reinforced by its expansion strategies and focus on personalized healthcare. Novartis AG (Switzerland) has strengthened its foothold by expanding its offerings with strategic acquisitions such as Kedalion Therapeutics. AbbVie Inc. (US) leverages product innovation, a high focus on R&D, and expansion to meet specific clinical needs and to enhance interoperability.

Related Reports:

Topical Drug Delivery Market by Product (Formulation (Semi-solid, Emulsion), Transdermal Patch, Microneedle Patch, Drug-in-adhesive, Matrix Patch), Application (Dermal, Ophthalmic, Nasal, Vaginal, Rectal), End User, Region - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com